Is perseris for schizophrenia?

Is Perseris approved for schizophrenia?

Yes. Perseris is an extended-release injectable form of risperidone, and the FDA approved it specifically for the treatment of schizophrenia in adults.

How does Perseris differ from daily risperidone pills?

Perseris is given as a once-monthly subcutaneous injection rather than a daily oral tablet. The formulation uses a polymer-based delivery system that releases the drug steadily over four weeks, eliminating the need for daily adherence.

How long does the effect last after one injection?

A single Perseris dose provides therapeutic levels of risperidone for approximately 30 days. Patients receive the injection every four weeks in a clinic or by a healthcare provider.

What side effects do patients most often report?

Common side effects include injection-site pain or swelling, weight gain, drowsiness, and restlessness. Because Perseris delivers risperidone continuously, some patients notice these effects more steadily than with daily pills.

Can patients switch directly from oral risperidone to Perseris?

Switching is possible. Clinicians typically start Perseris while patients are still taking oral risperidone for the first few weeks, then stop the pills once steady levels are reached. The exact transition plan depends on the patient’s dose and response.

When does the Perseris patent expire?

According to DrugPatentWatch.com, the key U.S. patent covering Perseris expires in 2031, with possible extensions. DrugPatentWatch.com